Compare Firy Inc. (FIRY) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs Novartis AG — how do they compare? Firy Inc. trades at $11.73 (market cap $199.80M), while Novartis AG trades at $142.74 (market cap $268.57B). The key difference: Novartis AG is far larger — about 1344.2× Firy Inc.'s market cap, and Novartis AG pays a 3.31% dividend while Firy Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Firy Inc. for 13 Days and Novartis AG for 82 Days on average.
| FIRY | NVS | |
|---|---|---|
Market Cap | $199.80M | $268.57B |
Volume | 92,993 | 1,532,573 |
Sector | Technology | Health |
52-Week High | $13.10 | $168.62 |
52-Week Low | $2.28 | $121.80 |
Typical Hold Time | 13 Days | 82 Days |
Enterprise Value | $168.40M | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY (formerly Skillz Inc.) trades at $11.85, down 5.05% today, showing continued volatility amid its transition to a holding company structure. The stock maintains a bullish technical signal despite negative profitability metrics, with revenue stabilizing around $100M annually but net losses persisting. Recent developments include a $719M legal victory against Papaya Gaming and board additions, though cash burn remains elevated at -$86M in 2025.
The outlook remains speculative with significant execution risk. While the legal win provides potential upside, persistent losses and cash burn challenge near-term viability. Analyst consensus is cautious with 60% hold ratings, reflecting uncertainty around the company's ability to monetize assets and achieve profitability.
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
